TriSalus Life Sciences (NASDAQ:TLSI) Stock Rating Lowered by Wall Street Zen

TriSalus Life Sciences (NASDAQ:TLSI) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

TLSI has been the subject of several other reports. Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Monday, December 29th. Zacks Research raised TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, December 16th. Finally, Canaccord Genuity Group upped their price objective on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $11.00.

TriSalus Life Sciences Trading Down 10.1%

TriSalus Life Sciences stock opened at $5.53 on Friday. TriSalus Life Sciences has a 1-year low of $3.42 and a 1-year high of $7.95. The firm has a market capitalization of $276.28 million, a PE ratio of -2.74 and a beta of 0.43. The firm’s 50 day simple moving average is $6.23 and its 200 day simple moving average is $5.24.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.79). The firm had revenue of $11.57 million for the quarter, compared to analysts’ expectations of $11.76 million. Research analysts forecast that TriSalus Life Sciences will post -1.55 earnings per share for the current year.

Institutional Trading of TriSalus Life Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of TLSI. Nantahala Capital Management LLC grew its position in TriSalus Life Sciences by 2.0% during the third quarter. Nantahala Capital Management LLC now owns 2,040,245 shares of the company’s stock valued at $9,487,000 after acquiring an additional 40,245 shares during the last quarter. AWM Investment Company Inc. purchased a new stake in shares of TriSalus Life Sciences in the 2nd quarter valued at $6,812,000. Vanguard Group Inc. grew its holdings in shares of TriSalus Life Sciences by 42.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock valued at $5,392,000 after purchasing an additional 345,186 shares during the last quarter. Gilder Gagnon Howe & Co. LLC raised its position in TriSalus Life Sciences by 32.1% in the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock worth $5,957,000 after purchasing an additional 265,618 shares during the period. Finally, Geode Capital Management LLC raised its position in TriSalus Life Sciences by 107.4% in the 2nd quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock worth $2,480,000 after purchasing an additional 235,627 shares during the period. Hedge funds and other institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.